<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109261</url>
  </required_header>
  <id_info>
    <org_study_id>PALBOCOMP</org_study_id>
    <nct_id>NCT04109261</nct_id>
  </id_info>
  <brief_title>Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe</brief_title>
  <acronym>PALBOCOMP</acronym>
  <official_title>Retrospective Observational Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fernando Moreno Antón</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital San Carlos, Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Spain, palbociclib was launched last November 1st, 2017. However, since February 2015 the&#xD;
      on-going compassionate use programme of palbociclib has enabled drug access to patients with&#xD;
      RH+/HER2- breast cancer previously treated with at least 4 treatment lines for advanced&#xD;
      disease. During this period, approximately 400 patients have received treatment within this&#xD;
      programme. Since this population of patients more pre-treated was not included in the studies&#xD;
      for regulatory submission, the collection of efficacy and toxicity data in the clinical&#xD;
      practice setting is of clinical interest.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>through study completion, up to 9 months</time_frame>
    <description>Number of days between the beginning of the treatment with palbociclib and the progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>through study completion, up to 9 months</time_frame>
    <description>Number of adverse events between the beginning of the treatment with palbociclib and the progression</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">237</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Palbociclib treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib administration in breast cancer patients included in a compassionate use programme. Patients were treated according to the standard of care</description>
    <arm_group_label>Palbociclib treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic breast cancer included in a compassionate use programme&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with RH+ y HER2- metastatic breast cancer having progressed to at least 4&#xD;
             previous standard treatment lines in the metastatic setting, and are not eligible to&#xD;
             receive palbociclib in a clinical trial&#xD;
&#xD;
          2. Absolute neutrophil count ≥1,500/mm3 (1.5 x 109/L)&#xD;
&#xD;
          3. Platelet count ≥100,000/mm3 (100 x 109/L)&#xD;
&#xD;
          4. Haemoglobin ≥9 g/dL&#xD;
&#xD;
          5. Creatinine ≤1.5 x ULN or creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          6. Total bilirubin ≤1.5 x ULN (≤3.0 x ULN in case of Gilbert's disease)&#xD;
&#xD;
          7. AST and/or ALT ≤3 x ULN (≤5.0 x ULN in case of hepatic metastases)&#xD;
&#xD;
          8. Alkaline phosphatase ≤2.5 x ULN (≤5.0 x ULN in case of hepatic or bone metastases)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major surgery, chemotherapy, radiotherapy, treatment with an investigational drug or&#xD;
             any other active anticancer therapy within two weeks of treatment initiation&#xD;
&#xD;
          2. Previous radiotherapy in ≥25% of bone marrow&#xD;
&#xD;
          3. QTc &gt;480 msec, personal or family past history of short or long QT syndrome, Brugada's&#xD;
             syndrome, or past history of QT interval prolongation, or tachycardia with Torsade de&#xD;
             Pointes (TdP)&#xD;
&#xD;
          4. History of any of the following conditions within 6 months of treatment initiation:&#xD;
             myocardial infarction, unstable angina, grade ≥2 arrhythmia (CTCAE version 4.0),&#xD;
             atrial fibrillation, coronary or peripheral artery by-pass, symptomatic congestive&#xD;
             heart failure, stroke, or pulmonary thromboembolism&#xD;
&#xD;
          5. Known hypersensitivity to palbociclib&#xD;
&#xD;
          6. Current or recent suicidal ideation or behaviour&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fernando Moreno</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Carlos, Madrid</investigator_affiliation>
    <investigator_full_name>Fernando Moreno Antón</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

